Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
出版年份 2022 全文链接
标题
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
作者
关键词
-
出版物
Lancet HIV
Volume 9, Issue 6, Pages e381-e393
出版商
Elsevier BV
发表日期
2022-04-21
DOI
10.1016/s2352-3018(22)00092-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line in adults failing a tenofovir-based first-line regimen
- (2021) Claire M. Keene et al. AIDS
- Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
- (2021) Nicholas I. Paton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
- (2021) Anna Turkova et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
- (2020) Willem D F Venter et al. Lancet HIV
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- (2020) Alexandra Calmy et al. Lancet HIV
- Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
- (2019) Michael Aboud et al. LANCET INFECTIOUS DISEASES
- A systematic review of the genetic mechanisms of dolutegravir resistance
- (2019) Soo-Yon Rhee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
- (2018) JR Santos et al. HIV MEDICINE
- HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies
- (2017) Erkki Lathouwers et al. HIV CLINICAL TRIALS
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial
- (2017) Laura Ciaffi et al. Lancet HIV
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
- (2017) Nicholas I Paton et al. Lancet HIV
- Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study
- (2016) Alberto M La Rosa et al. Lancet HIV
- Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa
- (2015) Laura Ciaffi et al. AIDS
- Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
- (2015) Mark A Boyd et al. Lancet HIV
- Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
- (2015) Nicholas I Paton et al. Lancet HIV
- Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
- (2014) Nicholas I. Paton et al. NEW ENGLAND JOURNAL OF MEDICINE
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now